- Male and female subjects aged ≥ 18, requiring intensive care treatment related to
secondary nosocomial sepsis, who require potent broad spectrum intravenous antibiotic
therapy.
You are here
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
NCT00318552
Last updated on
February 17, 2019
About this Study
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
Eligibility criteria
Condition
Sepsis
Sex
Females and Males
Age
18 + years
Inclusion criteria
Show details
Exclusion criteria
Show details
NCT00318552
Pfizer
Completed
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Based on your search, you may also be interested in
Pneumonia, Meningitis, Bacteremia, Sepsis
NCT00428051
All Genders
0+
Years
Multiple Sites
Sepsis
NCT00318552
All Genders
18+
Years
Multiple Sites
Late-onset Sepsis
NCT02424734
All Genders
0+
Years
Multiple Sites
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021